Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Nov;25(11):1333-1338.
doi: 10.1111/1756-185X.14425. Epub 2022 Aug 24.

Canakinumab treatment in a young girl with refractory chronic recurrent multifocal osteomyelitis associated with pyoderma gangrenosum

Sabrina Acierno  1 , Francesca Angrisani  1 , Achille Marino  2 , Roberto Felice Caporali  3   4 , Rolando Cimaz  2   3 , Teresa Giani  3
Affiliations
Case Reports

Canakinumab treatment in a young girl with refractory chronic recurrent multifocal osteomyelitis associated with pyoderma gangrenosum

Sabrina Acierno et al. Int J Rheum Dis. 2022 Nov.

Abstract

Background: Chronic recurrent multifocal osteomyelitis (CRMO) is a bone inflammatory disorder characterized by osteolytic, usually multiple, symmetric lesions. Diagnosis is one of exclusion, and no standardized therapies are available. Presumed deregulation of the interleukin (IL)-1β axis, as observed in 2 monogenic autoinflammatory conditions such as Majeed syndrome (LPIN2 mutations) and deficiency of IL-1 receptor antagonist (IL1RN mutations) with CRMO-like bone involvement, suggests the blockade of IL-1 as potentially useful also in this condition, even if scarce data are available.

Case presentation: We report the case of a 13-year-old girl affected by a multidrug-resistant and pyoderma gangrenosum-complicated CRMO treated with canakinumab, a human monoclonal antibody targeting IL-1β.

Conclusion: In this young patient pyoderma gangrenosum and CRMO showed a rapid and satisfactory response to canakinumab, although over time a decreased efficacy in controlling bone disease was observed.

Keywords: IL-1; anakinra; canakinumab; chronic recurrent multifocal osteomyelitis; pyoderma gangrenosum.

PubMed Disclaimer

References

REFERENCES

    1. Taddio A, Zennaro F, Pastore S, Cimaz R. An update on the pathogenesis and treatment of chronic recurrent multifocal osteomyelitis in children. Paediatr Drugs. 2017;19(3):165-172. doi:10.1007/s40272-017-0226-4
    1. Moreno-Mateo F, Perea SH, Onel KB. Chronic recurrent multifocal osteomyelitis: diagnosis and treatment. Curr Opin Pediatr. 2021;33(1):90-96. doi:10.1097/MOP.0000000000000970
    1. Zhao DY, McCann L, Hahn G, Hedrich CM. Chronic nonbacterial osteomyelitis (CNO) and chronic recurrent multifocal osteomyelitis (CRMO). J Transl Autoimmun. 2021;4:100095. doi:10.1016/j.jtauto.2021.100095
    1. Dagan O, Barak Y, Metzker A. Pyoderma gangrenosum and sterile multifocal osteomyelitis preceding the appearance of Takayasu arteritis. Pediatr Dermatol. 1995;12(1):39-42. doi:10.1111/j.1525-1470.1995.tb00122.x
    1. Samlaska CP, Smith RA, Myers JB, Bottini AG, Person DA. Pyoderma gangrenosum and cranial osteolysis: case report and review of the paediatric literature. Br J Dermatol. 1995;133(6):972-977. doi:10.1111/j.1365-2133.1995.tb06936.x

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources